V. Gueutin, G. Deray, and C. Isnard-bagnis, « Physiologie rénale, vol.99, issue.3, pp.237-249, 2012.

B. Lacour, Physiologie du rein et bases physiopathologiques des maladies rénales, vol.2013, pp.25-37, 2013.

. Pouteil-noble and . Insuffisance-rénale-chronique, Rev. Prat, vol.60, pp.1431-1442, 2010.

P. Jungers, D. Nguyen-khoa-man, and . Joly, Christophe Legendre, L'insuffisance rénale chronique : prévention et traitement, 2011.

J. F. Wetzels, L. A. Kiemeney, and D. W. Swinkels, Age and gender-specific reference values of estimated GFR in Caucasians, Nijmegen Biomed. Study, pp.632-637, 2007.

V. Bongard, « Estimation et caractérisation de l'insuffisance rénale chronique en France, Ann. Cardiol. Angéiologie, vol.61, issue.4, pp.239-244

L. Frimat, C. Loos-ayav, S. Briançon, and M. Kessler, Épidémiologie des maladies rénales chroniques, vol.2, pp.139-157, 2005.

C. Loos-ayav, S. Briançon, L. Frimat, J. André, and M. Kessler, Incidence de l'insuffisance rénale chronique en population générale, étude EPIRAN », Néphrologie Thérapeutique, vol.5, pp.250-255, 2009.

B. D. Coresh, B. C. Astor, and J. P. Briggs, Chronic Kidney Dis. Aware, 1999.

B. Stengel, C. Couchoud, C. Helmer, C. Loos-ayav, E. M. Kessler et al., , vol.36, pp.1811-1821, 2007.

F. Cannet-des-maures, F. Provence, S. L. Anaes, and D. La-plaine, « Moyens thérapeutiques pour ralentir la progression de l'insuffisance rénale chronique chez l'adulte Treatment strategies to slow the progression of chronic renal failure in adults, Néphrologie Thérapeutique, vol.1, pp.84-89, 2005.

B. Lacour, Z. Massy, and . Diagnostic, suivi biologique de l'insuffisance rénale chronique et prise en charge de l'insuffisance rénale chronique terminale, Rev. Francoph. Lab, vol.2013, pp.59-73, 2013.

J. Ifergan, L. Rocher, O. Hélénon, H. Oueslati, and M. Bellin, « Insuffisance rénale : stratégie diagnostique, J. Radiol, vol.92, issue.4, pp.299-307, 2011.

S. Charriere, N. Rognant, F. Chiche, A. Cremer, G. Deray et al., « Insuffisance rénale chronique et maladie cardiovasculaire, Ann. Cardiol. Angéiologie, vol.58, issue.1, pp.40-52, 2009.

P. Fesler and J. Ribstein, « Altération modérée de la fonction rénale et risque cardiovasculaire, Rev. Médecine Interne, vol.30, issue.7, pp.585-591, 2009.

P. D. , Dr Fitsum Guebre-Egziabher, « Maladie rénale chronique, Concours Méd, vol.135, issue.3, p.199, 2013.

F. Cannet-des-maures, F. Provence, S. L. Anaes, and D. La-plaine, « Moyens thérapeutiques pour ralentir la progression de l'insuffisance rénale chronique chez l'adulte Treatment strategies to slow the progression of chronic renal failure in adults, Néphrologie Thérapeutique, vol.1, pp.84-89, 2005.

M. Courbebaisse and J. Souberbielle, Équilibre phosphocalcique : régulation et explorations », Néphrologie Thérapeutique, vol.7, pp.118-138, 2011.

S. Kamel, T. Drueke, and E. Z. Massy, « Troubles minéraux et osseux de la maladie rénale chronique (TMO-MRC), Rev. Francoph. Lab, vol.2013, pp.29-43, 2013.

K. A. Hruska, S. Mathew, R. Lund, P. Qiu, and E. R. Pratt, Hyperphosphatemia of chronic kidney disease, vol.74, pp.148-157, 2008.

G. B. John and C. Cheng, Kuro-o, « Role of Klotho in Aging, Phosphate Metabolism, and CKD », Am. J. Kidney Dis, vol.58, issue.1, pp.127-134, 2011.

M. Lafage-proust,

C. Cormier, « Physiopathologie de l'hyperparathyroïdie secondaire de l'insuffisance rénale chronique

N. Souma, T. Isakova, D. Lipiszko, R. Sacco, M. Elkind et al., Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study, J Clin Endocrinol Metab, 2016.

J. Cunningham, F. Locatelli, and M. Rodriguez, Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options, vol.6, pp.913-921, 2011.

M. Lafage-proust, Insuffisance rénale et métabolisme du calcium et du phosphate, vol.79, pp.258-261, 2012.

J. Desoutter, R. Mentaverri, M. Brazier, S. Kamel, and . Le-remodelage-osseux-normal, Rev. Francoph. Lab, vol.2012, pp.33-42, 2012.

D. L. Andress, Adynamic bone in patients with chronic kidney disease, Kidney Int, vol.73, pp.1345-1354, 2008.

S. Moe, « Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, vol.69, issue.11, pp.1945-1953, 2006.

M. C. Vernejoul and P. Marie, Cellules osseuses et remodelage osseux. », 1993.

M. Jadoul, « Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study, Kidney Int, vol.70, pp.1358-1366, 2006.

M. L. Picton and . Down, regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure, Kidney Int, vol.58, pp.1440-1449, 2000.

. J. Bacchetta, .. S. Boutroy, and . F. Guebre-egziabher, The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease, vol.24, pp.3120-3125, 2009.

H. Horst-malluche, E. Ritz, H. Peter-lange, and J. Kutschera, Bone histology in incipient and advanced renal failure, vol.9, pp.355-362, 1976.

Y. Sabbagh, « Repression of osteocyte Wnt/?-catenin signaling is an early event in the progression of renal osteodystrophy, J. Bone Miner. Res, vol.27, issue.8, pp.1757-1772

N. Ghani, F. E. Abourazzak, and E. T. Harzy, Le remodelage osseux et ses implications thérapeutiques dans l'ostéoporose: mise au point », Rev. Marocaine Rhumatol, p.21, 2012.

S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie et al., Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo, Blood, vol.109, issue.5, pp.2106-2111, 2007.

C. Hercz, Y. Pei, C. Greenwood, A. Manuel, C. Saiphoo et al., Aplastic osteodystrophy without aluminium: The role of suppressed parathyroid function, Kidney Int, vol.44, pp.860-866, 1993.

R. Oprisiu, « Ostéodystrophie rénale (1); diagnostic invasif et non invasif des variétés histopathologiques, vol.21, pp.229-237, 2000.

S. J. Solal, M. E. Boudailliez, B. Et-marie, and A. , « Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. », J Clin Endocrinol Metab, vol.73, issue.3, pp.516-540, 1991.

N. K. Man and P. Jungers, Désordres du métabolisme phospho-calcique et complications ostéoarticulaires, 2007.

F. Llach, A. J. Felsenfeld, M. D. Coleman, K. Et, and . Jj, The natural course of dialysis osteomalacia, vol.18, pp.74-79, 1986.

A. Fournier, A. Marie, E. Esper, and N. , Osteodystrophie rénale. Aspects clinicoradiologiques, physiopathologie et traitement. », Encycl. Méd.-Chir, vol.18, pp.1-16, 1994.

S. Andreoli, J. Bergstein, D. Sherrard, and «. , Aluminum intoxication from aluminum containing phosphate binders in children with azotemia not undergoing dialysis, N Engl JM, vol.310, pp.1079-83, 1984.

P. Schrooten-i,-d'haese, W. Cabrera, and «. , Experimental evidence for strontium to play a role in the development of dialysis related osteomalacia. », J Am Soc Nephrol, vol.8, p.555, 1997.

A. Ghazali, « Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?, Kidney Int, vol.55, issue.6, pp.2169-2177, 1999.

R. Demontis, P. F. Westeel, B. Boudalliez, P. Morinière, and A. Et-leflon, « 1?OH vitamin D3 increases plasma aluminum in hemodialyzed patients taking AlOH3, vol.33, pp.175-177, 1988.

R. Chapurlat and D. Chappard, L'ostéoporose, mieux la comprendre pour mieux la traiter, 2009.

M. Rix, H. Andreassen, and P. Eskildsen, Bente Langdahl, et Klaus Olgaard, « Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure, Kidney Int, vol.56, pp.1084-1093, 1999.

A. M. Alem, « Increased risk of hip fracture among patients with end-stage renal disease, Kidney Int, vol.58, issue.1, pp.396-399, 2000.

C. O. Stehman-breen, « Risk factors for hip fracture among patients with end-stage renal disease, Kidney Int, vol.58, issue.5, pp.2200-2205, 2000.

J. S. Kriegshauser, R. G. Swee, M. Carthy, J. T. Hauser, and M. F. , Aluminium toxicity in patients undergoing dialysis: radiographic findings and prediction of bone biopsy results, vol.164, pp.399-403, 1987.

P. C. D'haese, M. Couttenye, and M. E. De-broe, Nephrol. Dial. Transplant, vol.11, pp.74-79, 1996.

K. A. Smans and G. F. Van-landeghem, Haese PC, « Aluminium transferrin but not Al citrate uptake by the parathyroid gland may contribute to the development of hypoparathyroidism associated with adynamic bone disease, J Am Soc Nephrol, vol.6, p.940, 1995.

R. Brown, J. Aston, . Weeks, and . Woodhead, « Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay, J Clin Endocrinol Metab, vol.65, issue.3, pp.407-414, 1987.

M. Wang, G. Hercz, D. Sherrard, N. Maloney, G. Segre et al., « Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity », Am J Kidney Dis, vol.26, issue.5, pp.836-880, 1995.

. Sharon-m-moe, B. Tilman, and . Drueke, Recommandations KDIGO de bonnes pratiques cliniques pour le diagnostic, l'évaluation, la prévention et le traitement des troubles minéraux et osseux associés aux maladies rénales chroniques

R. Oprisiu, « Ostéodystrophie rénale (1); diagnostic invasif et non invasif des variétés histopathologiques, vol.21, pp.229-237, 2000.

H. E. Meema, D. G. Oreopoulos, S. Rabinovich, H. Husdan, and A. Rapoport, Periosteal New Bone Formation, vol.110, 1974.

A. Fournier, S. Said, and A. Et-ghazali, , pp.96-128, 1997.

H. Schober, « Mineralized bone loss at different sites in dialysis patients: implications for prevention. », J. Am. Soc. Nephrol, vol.9, issue.7, pp.1225-1233, 1998.

I. Mucsi and . Hercz, Adynamic bone disease : Pathogenesis, diagnosis and clinical relevance, Curr Opin Nephrol Hypertens, issue.6, pp.356-61, 1997.

E. Slatopolsky, S. Burke, and . Dillon, Kidney Int, vol.55, pp.299-307, 1999.

A. L. De-francisco, « Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability, Nephrol. Dial. Transplant, vol.25, issue.11, pp.3707-3717, 2010.

A. T. Neveen, J. A. Hamdy, M. Kanis, C. B. Beneton, J. R. Brown et al.,

G. M. Johannes and . Jordans, Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure, BMJ, vol.310, pp.358-363, 1995.

E. Ritz, « Low-dose calcitriol prevents the rise of 1-84 PTH without affecting serum calcium and phosphate in patients with moderate renal failure, Nephrol Dial Transpl, vol.10, pp.2228-2262, 1995.

M. Rix, P. Eskildsen, and K. Olgaard, « Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure, Nephrol Dial Transpl, vol.19, pp.870-876, 2004.

P. Urena and . Parathyroid, Nephrologie, vol.23, issue.4, pp.151-164, 2002.

G. A. Block, « Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, N. Engl. J. Med, vol.350, pp.1516-1525, 2004.

J. M. Frazão, P. Messa, G. J. Mellotte, H. Geiger, E. C. Hagen et al., « Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity, Clin Nephrol, vol.76, pp.233-276, 2011.

L. Harbouche, Place des nouveaux traitements de l'ostéodystrophie rénale : dérivés 1?hydroxylés de la vitamine D « non hypercalcémiants », complexants non calciques, non magnésiens et non aluminiques des phosphates, vol.21, pp.9-32, 2006.

A. Fournier, « Comparison of 1?-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization, Kidney Int, vol.15, issue.2, pp.196-204, 1979.

P. Morinière, S. Cohen, S. Belbrik, J. L. Sebert, and A. Fournier, « Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum, Nephron, vol.56, pp.93-101, 1989.

I. Legroux-gérot, Reflex. Rhumatol, vol.16, pp.11-15, 2012.

J. Torregrosa, A. Moreno, M. Mas, J. Ybarra, and E. D. Fuster, Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis, Kidney Int, vol.63, pp.88-90, 2003.

E. Hernández, « Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis, Kidney Int, vol.63, issue.6, pp.2269-2274, 2003.

A. Ishani, T. Blackwell, S. A. Jamal, S. R. Cummings, and K. E. Ensrud, et for the MORE Investigators, « The Effect of Raloxifene Treatment in Postmenopausal Women with CKD, J. Am. Soc. Nephrol, vol.19, issue.7, pp.1430-1438, 2008.

R. Baron and G. Rawadi, « Targeting the Wnt/?-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton, Endocrinology, vol.148, issue.6, pp.2635-2643, 2007.

C. Krause, « Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways, J. Biol. Chem, vol.285, pp.41614-41626

R. J. Lund, Successful Treatment of an Adynamic Bone Disorder with Bone Morphogenetic Protein-7 in a Renal Ablation Model, J. Am. Soc. Nephrol, vol.15, issue.2, pp.359-369, 2004.

X. Li, « Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*, J. Bone Miner. Res, vol.24, issue.4, pp.578-588, 2009.

F. Cosman, « Romosozumab Treatment in Postmenopausal Women with Osteoporosis, N. Engl. J. Med, vol.375, pp.1532-1543, 2016.

D. Cejka, K. Kodras, T. Bader, and E. M. Haas, « Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH<sub>1-34</sub>): A Pilot Study, Kidney Blood Press. Res, vol.33, issue.3, pp.221-226, 2010.

M. Jannot, Profil d' expression ostéocytaire et troubles de la minéralisation et du remodelage osseux dans l'ostéodystrophie rénale, 2017.

A. Rossier, R. Bullani, D. Teta, and M. Et-birnier, Bicarbonate de sodium pour ralentir la progression de la maladie rénale chronique, Rev. Médicale Suisse, pp.478-82, 2011.

T. Remer, F. Manz, and «. , Potential renal acid load of foods and its influence on urine pH, J Am Diet Assoc, vol.95, pp.791-797, 1995.

L. Leiter, « Les tomates préviennent-elles l'ostéoporose? », Endocrinologie, vol.5, 2005.

S. Silverton and . Osteoclast, J Cell Biochem, vol.56, issue.3, pp.367-73, 1994.

B. E. Bax, « Stimulation of osteoclastic bone resorption by hydrogen peroxide, Biochem. Biophys. Res. Commun, vol.183, issue.3, pp.1153-1158, 1992.

L. L. Key, W. L. Ries, R. G. Taylor, B. D. Hays, and B. L. Pitzer, Oxygen derived free radicals in osteoclasts: The specificity and location of the nitroblue tetrazolium reaction, vol.11, pp.115-119, 1990.

A. Mortensen, L. H. Skibsted, J. Sampson, and C. Et-rice-evans, Comparative mechanisms and rates of free radical scavenging by carotenoid antioxidants, vol.418, pp.91-97, 1997.

N. Angelloz-nicoud, Principes de l'alimentation santé

G. D. Miller and «. , The importance of meeting calcium needs with foods, J Am Coll Nutr, vol.20, pp.85-165, 2001.

P. Kandula, M. Dobre, J. D. Schold, M. J. Schreiber, R. Mehrotra et al., « Vitamin D Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials », Clin. J. Am. Soc. Nephrol, vol.6, issue.1, pp.50-62, 2011.

G. Jean, J. Souberbielle, and C. Chazot, « Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation, Nephrol. Dial. Transplant, vol.24, pp.3799-3805, 2009.

V. Amstutz, B. Favrat, J. Cornuz, and M. Krieg, Vitamine D: actualité et recommandations

J. G. Haddad, L. Y. Matsuoka, B. W. Hollis, Y. Z. Hu, and E. J. Wortsman, « Human plasma transport of vitamin D after its endogenous synthesis. », J. Clin. Invest, vol.91, issue.6, p.2552, 1993.

P. Mh-lafage, La Biopsie osseuse à visée histomorphométrique, 2015.

A. S. Go, G. M. Chertow, D. Fan, C. E. Mcculloch, and C. Hsu, « Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N. Engl. J. Med, vol.351, issue.13, pp.1296-1305, 2004.